Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.
1. A method for treating, preventing, or delaying onset of corneal graft rejection after corneal transplant, comprising administering to an eye of a subject that has undergone corneal transplant an effective amount of a compound selected from the group consisting of axitinib, cediranib, linifanib, motesanib, nintedanib, pazopanib, regorafenib, sunitinib, tivozanib, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is administered in an amount effective to prevent graft rejection by inhibiting abnormal neovascularization and inflammation in the eye of the subject.
3. The method of claim 1 , wherein the subject has a condition selected from the group consisting of graft versus host disease, atopic conjunctivitis, ocular rosacea, ocular pemphigoid, Lyell's syndrome, contact lens induced neovascularization, ulceration, alkali burns, stem cell deficiency, pinguecula, neovascular glaucoma, dry eye disease, Sjogren's syndrome, Meibomian gland dysfunction, Steven Johnson syndrome, tumor in the eye, and neovascularization induced by viral, bacterial, fungal, or parasitic infection.
4. The method of claim 1 , wherein the compound is administered in the form of topical ocular formulation or ocular implant.
5. The method of claim 4 , wherein the ocular implant is in the form of a semi-solid or solid sustained-release implant.
6. The method of claim 5 , wherein the implant is injected into the eye of the subject.
7. The method of claim 4 , wherein the topical ocular formulation is a topical eye drop.
8. The method of claim 4 , wherein the topical ocular formulation is a solution, suspension, cream, ointment, gel, gel-forming liquid, suspension containing liposomes or micelles, spray formulation, or emulsion.
9. The method of claim 1 , further comprising administering to the eye of the subject an effective amount of an antimetabolite.
10. The method of claim 9 , wherein the antimetabolite is selected from the group consisting of mycophenolate mofetil, methotrexate, mitomycin C, 5-fluorouracil, azathioprine, and thiotepa.